Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04703842 · ClinicalTrials.gov registry record · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
A Phase 1 study of Heart Failure and Congestive Heart Failure, sponsored by Sardocor.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
- 5
- Study locations
NCT04703842 is a Phase 1 study of Heart Failure and Congestive Heart Failure that is actively recruiting participants, run by Sardocor. The registered enrollment target is 57 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT04703842, a Phase 1 study of Heart Failure and Congestive Heart Failure, is actively recruiting participants, sponsored by Sardocor.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
- 5
- Study locations
Study Summary
It is believed that targeted SERCA2a enzyme replacement in HFrEF patients will correct defective intracellular Ca2+ hemostasis, resulting in improved cardiac contractile function and energetics which will, in turn, translate to improved clinical outcomes. Additionally, it is hypothesized that correcting SERCA2a dysfunction will also improve coronary blood flow through correction of the impaired endothelium-dependent nitric oxide-mediated vasodilatation observed in heart failure.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL SRD-001
Study Locations (5)
California
- San Diego Cardiac Center - San Diego
- University of California, San Francisco - San Francisco
Missouri
- Washington University in Saint Louis - St Louis
Texas
- University of Texas Southwestern Medical Center - Dallas
Washington
- University of Washington Medicine - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2021-09-23 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04703842
The ClinicalTrials.gov registry entry for NCT04703842 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower). The listed sponsor is Sardocor, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04703842 reports 5 study locations spanning 4 distinct geographic areas - top geographies include California, Missouri, Texas.
Frequently Asked Questions
What is clinical trial NCT04703842 about?
NCT04703842 is a clinical study titled "Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction". It is believed that targeted SERCA2a enzyme replacement in HFrEF patients will correct defective intracellular Ca2+ hemostasis, resulting in improved cardiac contractile function and energetics which will, in turn, translate to improved clinical outcomes. Additionally, it is hypothesized that correc...
What is the current status of trial NCT04703842?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2021-09-23. Estimated completion is 2028-12.
What conditions does trial NCT04703842 study?
This clinical trial studies the following conditions: Heart Failure, Congestive Heart Failure, Heart Failure, Systolic, HFrEF - Heart Failure With Reduced Ejection Fraction.
What interventions are being tested in trial NCT04703842?
The interventions under investigation include: Placebo (DRUG), SRD-001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04703842?
This trial is sponsored by Sardocor, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04703842 being conducted?
This trial has 5 study locations across California, Missouri, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mechanisms of Semaglutide Therapy in Heart Failure Patients
RECRUITING · Phase 1
-
The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART)
RECRUITING · Phase 1
-
Mechanisms of Diuretic Resistance in Heart Failure, Aim 3
RECRUITING · Phase 1
-
Mechanisms of Diuretic Resistance in Heart Failure, Aim 1
RECRUITING · Phase 1
-
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
RECRUITING · Phase 1
-
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.